Literature DB >> 33543129

Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury.

Etienne Laverse1, Tong Guo1, Karl Zimmerman2, Martha S Foiani3, Bharat Velani1, Philip Morrow4, Ademola Adejuwon5, Richard Bamford4, Natasha Underwood4, Jonathan George4, Daniel Brooke5, Karen O'Brien6, Matthew J Cross7, Simon P T Kemp8, Amanda J Heslegrave3, John Hardy3, David J Sharp2, Henrik Zetterberg3, Huw R Morris1.   

Abstract

Mild traumatic brain injury is a relatively common event in contact sports and there is increasing interest in the long-term neurocognitive effects. The diagnosis largely relies on symptom reporting and there is a need for objective tools to aid diagnosis and prognosis. There are recent reports that blood biomarkers could potentially help triage patients with suspected injury and normal CT findings. We have measured plasma concentrations of glial and neuronal proteins and explored their potential in the assessment of mild traumatic brain injury in contact sport. We recruited a prospective cohort of active male rugby players, who had pre-season baseline plasma sampling. From this prospective cohort, we recruited 25 players diagnosed with mild traumatic brain injury. We sampled post-match rugby players without head injuries as post-match controls. We measured plasma neurofilament light chain, tau and glial fibrillary acidic protein levels using ultrasensitive single molecule array technology. The data were analysed at the group and individual player level. Plasma glial fibrillary acidic protein concentration was significantly increased 1-h post-injury in mild traumatic brain injury cases compared to the non-injured group (P = 0.017). Pairwise comparison also showed that glial fibrillary acidic protein levels were higher in players after a head injury in comparison to their pre-season levels at both 1-h and 3- to 10-day post-injury time points (P = 0.039 and 0.040, respectively). There was also an increase in neurofilament light chain concentration in brain injury cases compared to the pre-season levels within the same individual at both time points (P = 0.023 and 0.002, respectively). Tau was elevated in both the non-injured control group and the 1-h post-injury group compared to pre-season levels (P = 0.007 and 0.015, respectively). Furthermore, receiver operating characteristic analysis showed that glial fibrillary acidic protein and neurofilament light chain can separate head injury cases from control players. The highest diagnostic power was detected when biomarkers were combined in differentiating 1-h post-match control players from 1-h post-head injury players (area under curve 0.90, 95% confidence interval 0.79-1.00, P < 0.0002). The brain astrocytic marker glial fibrillary acidic protein is elevated in blood 1 h after mild traumatic brain injury and in combination with neurofilament light chain displayed the potential as a reliable biomarker for brain injury evaluation. Plasma total tau is elevated following competitive rugby with and without a head injury, perhaps related to peripheral nerve trauma and therefore total tau does not appear to be suitable as a blood biomarker.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

Entities:  

Keywords:  GFAP; NFL; biomarkers; concussion; mild-TBI

Year:  2020        PMID: 33543129      PMCID: PMC7846133          DOI: 10.1093/braincomms/fcaa137

Source DB:  PubMed          Journal:  Brain Commun        ISSN: 2632-1297


  37 in total

Review 1.  Diagnosis, prognosis, and clinical management of mild traumatic brain injury.

Authors:  Harvey S Levin; Ramon R Diaz-Arrastia
Journal:  Lancet Neurol       Date:  2015-03-20       Impact factor: 44.182

2.  Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study.

Authors:  Jeffrey J Bazarian; Peter Biberthaler; Robert D Welch; Lawrence M Lewis; Pal Barzo; Viktoria Bogner-Flatz; P Gunnar Brolinson; Andras Büki; James Y Chen; Robert H Christenson; Dallas Hack; J Stephen Huff; Sandeep Johar; J Dedrick Jordan; Bernd A Leidel; Tobias Lindner; Elizabeth Ludington; David O Okonkwo; Joseph Ornato; W Frank Peacock; Kara Schmidt; Joseph A Tyndall; Arastoo Vossough; Andy S Jagoda
Journal:  Lancet Neurol       Date:  2018-07-24       Impact factor: 44.182

Review 3.  Astrocyte intermediate filaments in CNS pathologies and regeneration.

Authors:  Milos Pekny; Marcela Pekna
Journal:  J Pathol       Date:  2004-11       Impact factor: 7.996

Review 4.  Systematic review of prognosis and return to play after sport concussion: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis.

Authors:  Carol Cancelliere; Cesar A Hincapié; Michelle Keightley; Alison K Godbolt; Pierre Côté; Vicki L Kristman; Britt-Marie Stålnacke; Linda J Carroll; Ryan Hung; Jörgen Borg; Catharina Nygren-de Boussard; Victor G Coronado; James Donovan; J David Cassidy
Journal:  Arch Phys Med Rehabil       Date:  2014-03       Impact factor: 3.966

5.  Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system.

Authors:  M Goedert; M G Spillantini; R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 6.  Blood biomarkers for brain injury: What are we measuring?

Authors:  Keisuke Kawata; Charles Y Liu; Steven F Merkel; Servio H Ramirez; Ryan T Tierney; Dianne Langford
Journal:  Neurosci Biobehav Rev       Date:  2016-05-12       Impact factor: 8.989

7.  Serum Neurofilament Light in American Football Athletes over the Course of a Season.

Authors:  Jonathan M Oliver; Margaret T Jones; K Michele Kirk; David A Gable; Justin T Repshas; Torie A Johnson; Ulf Andréasson; Niklas Norgren; Kaj Blennow; Henrik Zetterberg
Journal:  J Neurotrauma       Date:  2016-03-16       Impact factor: 5.269

8.  Blood biomarkers for brain injury in concussed professional ice hockey players.

Authors:  Pashtun Shahim; Yelverton Tegner; David H Wilson; Jeffrey Randall; Tobias Skillbäck; David Pazooki; Birgitta Kallberg; Kaj Blennow; Henrik Zetterberg
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

9.  Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations.

Authors:  David M Rissin; Cheuk W Kan; Todd G Campbell; Stuart C Howes; David R Fournier; Linan Song; Tomasz Piech; Purvish P Patel; Lei Chang; Andrew J Rivnak; Evan P Ferrell; Jeffrey D Randall; Gail K Provuncher; David R Walt; David C Duffy
Journal:  Nat Biotechnol       Date:  2010-05-23       Impact factor: 54.908

10.  Myelin Water Fraction Is Transiently Reduced after a Single Mild Traumatic Brain Injury--A Prospective Cohort Study in Collegiate Hockey Players.

Authors:  Alexander D Wright; Michael Jarrett; Irene Vavasour; Elham Shahinfard; Shannon Kolind; Paul van Donkelaar; Jack Taunton; David Li; Alexander Rauscher
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

View more
  3 in total

1.  Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults.

Authors:  Lise Beier Havdal; Lise Lund Berven; Joel Selvakumar; Tonje Stiansen-Sonerud; Truls Michael Leegaard; Trygve Tjade; Henrik Zetterberg; Kaj Blennow; Vegard Bruun Bratholm Wyller
Journal:  Front Neurol       Date:  2022-06-22       Impact factor: 4.086

2.  Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients.

Authors:  Rebecca Halbgebauer; Steffen Halbgebauer; Patrick Oeckl; Petra Steinacker; Eberhard Weihe; Martin K-H Schafer; Francesco Roselli; Florian Gebhard; Markus Huber-Lang; Markus Otto
Journal:  Int J Mol Sci       Date:  2022-08-25       Impact factor: 6.208

Review 3.  Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis.

Authors:  Arvid Edén; Joel Simrén; Richard W Price; Henrik Zetterberg; Magnus Gisslén
Journal:  J Neurochem       Date:  2021-08-20       Impact factor: 5.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.